JBCHEPHARM.BOJBCHEPHARM.BOBSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +14.09% | +10.18% | +8.91% | +8.42% | +10.51% |
| Gross Profit Growth | +13.29% | +70.60% | +11.57% | +64.40% | -22.92% |
| EBITDA Growth | +13.90% | +3.73% | +10.19% | +15.86% | +19.65% |
| Operating Income Growth | +12.42% | +683.47% | +7.75% | +15.97% | +17.83% |
| Net Income Growth | +21.65% | +15.48% | +14.45% | +19.05% | +21.79% |
| EPS Growth | +21.35% | +15.13% | +13.87% | +18.24% | +20.75% |
| EPS Diluted Growth | +21.04% | +13.77% | +14.25% | +18.91% | +21.58% |
| Weighted Average Shares Growth | +0.19% | +2.47% | +0.56% | +0.68% | +0.84% |
| Weighted Average Shares Diluted Growth | +0.51% | +0.63% | +2.28% | +0.12% | +0.17% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -5.21% | +0.00% | +14.83% | +0.00% |
| Inventory Growth | +0.00% | +5.26% | +0.00% | +6.05% | +0.00% |
| Asset Growth | +0.00% | +7.00% | +0.00% | +16.95% | +0.00% |
| Book Value per Share Growth | +18.01% | +14.61% | +16.80% | +17.67% | +0.00% |
| Debt Growth | +0.00% | -92.62% | +0.00% | -59.18% | +0.00% |
| R&D Expense Growth | +0.00% | +22.32% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | -100.00% | -51.21% | +15.78% | -100.00% | +0.00% |